The timing alone raises eyebrows.
Less than a month after scrubbing "Domain Therapeutics" from its letterhead, the newly christened Kainova Therapeutics locked down C$32 million in a first-tranche Series B close on February 10, 2026. The speed suggests something had been brewing well before the January rebrand—and perhaps that the company's clinical momentum is starting to turn heads in what CEO Sean A. MacDonald openly describes as "a challenging fundraising environment."
Investissement Québec, the provincial investment arm, anchored the round and brought Kainova's headquarters north to Montréal in the process. The syndicate sprawls across three continents: CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare BioInnovations, and Seido Capital all joined. It's the kind of investor roster that signals credible science and, crucially, enough traction to overcome the risk-aversion that's gripped venture capital for the better part of two years.
The money will propel three GPCR-targeting programs deeper into the clinic. DT-7012, an anti-CCR8 antibody, is already enrolling patients in a Phase I/II trial for immuno-oncology. DT-9081, an EP4 antagonist, finished Phase I last July and is being prepped for oncology expansion. Then there's DT-9046, a PAR2 biased antagonist chasing inflammatory conditions like atopic dermatitis, inflammatory bowel disease, and arthritis—therapeutic areas where unmet need remains high and commercial potential, if the science holds, considerable.
Québec Makes Its Move
Investissement Québec's involvement isn't just financial theater. The agency is betting on Kainova becoming another node in Québec's increasingly ambitious life sciences cluster. Louis-Étienne Fortier from the investment arm joined Kainova's board as part of the deal—a signal that this is more than a passive check-writing exercise.
Kainova now operates its headquarters in Montréal, with a research footprint in Strasbourg, France, and clinical operations running out of Australia. It's a distributed model, common enough in biotech but one that requires tight coordination when trials are moving.
"This financing validates our strategy and pipeline," MacDonald said in the company's announcement. The statement reads carefully—measured optimism without the hyperbole that venture-backed CEOs sometimes lean into. He's been in the industry long enough to know how quickly momentum can stall.
Clinical Data Starts to Accumulate
The DOMISOL trial, testing DT-7012, launched last June across multiple Australian sites. The design is open-label: monotherapy dose escalation followed by combination testing with an immune checkpoint inhibitor. Kainova is targeting 125 patients, with primary completion estimated for September 2027—assuming enrollment stays on track, which in oncology trials is never guaranteed.
The antibody works by selectively depleting CCR8-positive regulatory T cells while maintaining antagonist activity in CCL1-rich tumor environments. That's a mouthful, but the differentiation matters in a space where Coherus BioSciences is advancing CHS-114, its own afucosylated anti-CCR8 candidate, in Phase 1 combination studies. Coherus has deeper pockets and a head start in the clinic. Kainova will need to demonstrate either superior efficacy or a cleaner safety profile to carve out room.
DT-9081 wrapped its Phase I EPRAD trial in July 2025 after dosing 29 patients across European sites. At the American Association for Cancer Research meeting last year, Kainova presented pharmacokinetic, pharmacodynamic, and safety data that pointed to 600 mg as the recommended Phase 2 dose. One-third of evaluable patients showed stable disease after two cycles—a modest but not insignificant signal in early-stage oncology.
The European Patent Office granted composition-of-matter protection for the EP4 antagonist series through October 2040, giving Kainova runway to operate without immediate patent cliff anxieties. Meanwhile, Ono Pharmaceutical's competing EP4 antagonist, ONO-4578, met its primary progression-free survival endpoint in a Phase 2 gastric cancer combo study with Opdivo and chemotherapy in 2025. That result doesn't guarantee success for Kainova's candidate, but it does validate the mechanism—and validation, in drug development, is worth something.
Rebrand Reflects a Shift in Identity
The January 12 rebrand from Domain Therapeutics to Kainova wasn't cosmetic. MacDonald, in a mid-January interview, framed it as a pivot from discovery-stage platform to clinical executor—a company no longer defined by its GPCR screening technology but by the drugs in its pipeline.
The name itself is a mashup: "Kairos," the ancient Greek word for opportune timing, fused with "Nova," meaning new. The pipeline codes—DT-7012, DT-9081, DT-9046—stayed intact, which is practical if slightly inelegant. Rebranding those would have created headaches in regulatory filings.
Kainova raised US$42 million in a May 2022 Series A co-led by Panacea Venture, CTI Life Sciences, and 3B Future Health Fund. The company also holds partnering agreements with Merck KGaA on adenosine receptor antagonists (with milestone payments potentially reaching €240 million) and Boehringer Ingelheim on CNS GPCR targets. Those partnerships provide non-dilutive funding but also impose timelines and expectations that the company will need to meet.
What Comes Next
The C$32 million figure is labeled a "first close," which in venture parlance means more investors could pile in. Whether Kainova extends the round will likely depend on how clinical data shapes up over the next several months.
MacDonald told reporters in January that 2026 milestones would include updates from higher-dose cohorts of the DOMISOL trial and broader clinical progress across the pipeline. The company bolstered its leadership last November by appointing Jean-Marie Cuillerot as chief medical officer. Cuillerot's résumé runs deep: former CMO roles at Acrivon, Dragonfly Therapeutics, and Agenus, with prior stints developing Bristol Myers Squibb's ipilimumab and EMD Serono's avelumab. In biotech, pedigree matters—and Cuillerot's track record suggests Kainova is preparing for pivotal-stage trials sooner rather than later.
For now, the company has cash, a syndicate spanning three continents, and a CEO who seems acutely aware of the tightrope he's walking. Clinical data in oncology can be mercurial. But if DT-7012 or DT-9081 delivers a meaningful signal in the next eighteen months, Kainova could find itself in a very different conversation with investors—and perhaps with acquirers.
